Cipla aims to venture into India’s weight loss drug market

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

Listen to the Article (6 Minutes)

From crossing $900 million in US sales in the fiscal year 2024 to holding the top position as a prescription company in South Africa, Cipla showcased positive numbers across various fronts.

The pharmaceutical giant also revealed its strategic intent to venture into the weight loss segment in India, tapping into the growing demand for solutions to combat obesity.

While Cipla is working on an obesity drug, the pharma major is also open to market US drugmaker Eli Lilly’s weight loss drugs in India. The drugmaker already has an existing partnership with Lilly to sell and promote Eli Lilly’s diabetes drugs in the country.

Cipla emphasised its focus on maintaining a base-level margin of $215 million to $220 million for its US operations, demonstrating a strategic balance between growth and profitability.

Also Read: Cipla Q4 Results: Topline and margins below estimates; ₹13 per share dividend announced

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow